Figure 2
The EBF3 promoter is methylated in AML cell lines. (A) Two CpG island regions can be identified in the promoter of EBF3. (B) MSP analysis of the methylation status of EBF3 in leukemia cell lines shows that the promoter is hypermethylated in 10/12 cell lines. M and U represents MSP results using primer sets for methylated and unmethylated EBF3 genes, respectively. (C) PCR analysis showed that the methylation status of EBF3 decreased in leukemia cells following 5-Aza treatment compared with control cells treated with DMSO. The transcript level of EBF3 is significantly upregulated in HL-60 and NB4 cells treated with 5-Aza compared with those treated with DMSO. *P < 0.05; **P < 0.01.